Tsuchida Y, Usui M, Naitoh T, Takahashi T, Murakami M, Uede T
Department of Orthopedic Surgery, Sapporo Medical University, Japan.
J Reconstr Microsurg. 1997 Feb;13(2):107-10. doi: 10.1055/s-2007-1000225.
This study examined whether administration of anti-ICAM-1 mAb (monoclonal antibody) and anti-LFA-1 mAb were effective for inhibition of the acute rejection reaction in a rat-limb allograft model. The grafts were carried out using major histocompatibility complex mismatch pairs of rats: ACI rats as the donors and Lewis rats as the recipients. The subjects were of species with completely different major histocompatibility complexes. The average length of survival in this combination was 4.7 +/- 0.6 days. When anti-ICAM-1, anti-LFA-1 mAb, or a combination of both were administered intraperitoneally at 1 mg/kg body weight daily for 7 days after the graft, the mean survival times were 4.3 +/- 0.6, 4.7 +/- 0.6, or 4.7 +/- 0.6 days, respectively. The agents were found to exercise no beneficial effects for transplants. Transplants were then carried out with a single intramuscular administration of FK506 at 3mg/kg body weight on the day of the operation to observe the effect of this adjunct therapy. The mean survival time averaged 16.0 +/- 5.5 days with FK506 alone. Administration of anti-ICAM-1, anti-LFA-1, and both antibodies together with FK506 resulted in mean survival times of 15.4 +/- 3.0, 25.0 +/- 5.8 and 13.2 +/- 5.8 days, respectively. Thus, a significant prolongation of survival time was observed when the combination of anti-LFA-1 mAb and FK506 was used. In contrast, anti-ICAM-1 mAb and FK506 or both mAb and FK506 showed no beneficial effects.
本研究检测了抗细胞间黏附分子-1单克隆抗体（mAb）和抗淋巴细胞功能相关抗原-1单克隆抗体对大鼠肢体同种异体移植模型急性排斥反应的抑制效果。移植采用主要组织相容性复合体不匹配的大鼠对：以ACI大鼠作为供体，Lewis大鼠作为受体。实验对象为主要组织相容性复合体完全不同的物种。这种组合下的平均存活时间为4.7±0.6天。在移植后每天以1mg/kg体重的剂量腹腔注射抗细胞间黏附分子-1、抗淋巴细胞功能相关抗原-1单克隆抗体或两者的组合，持续7天，平均存活时间分别为4.3±0.6天、4.7±0.6天或4.7±0.6天。发现这些药物对移植没有有益作用。然后在手术当天以3mg/kg体重单次肌肉注射FK506进行移植，以观察这种辅助治疗的效果。单独使用FK506时平均存活时间为16.0±5.5天。抗细胞间黏附分子-1、抗淋巴细胞功能相关抗原-1以及两种抗体与FK506联合使用时，平均存活时间分别为15.4±3.0天、25.0±5.8天和13.2±5.8天。因此，当使用抗淋巴细胞功能相关抗原-1单克隆抗体和FK506联合治疗时，观察到存活时间显著延长。相比之下，抗细胞间黏附分子-1单克隆抗体与FK506联合或两种单克隆抗体与FK506联合均未显示出有益效果。
